Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Loss Could Be Nabi’s Gain In Stop-Smoking Space

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase II vaccine, unlike Chantix, does not cross blood-brain barrier.

You may also be interested in...



GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX

Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.

GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX

Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.

Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M

The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel